A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer

Trial Profile

A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs GEN 1 (Primary) ; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms GOG
  • Most Recent Events

    • 09 Aug 2017 Results published in the Gynecologic Oncology
    • 01 Aug 2017 Status changed from completed to active, no longer recruiting.
    • 01 Aug 2017 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top